Tolerability in patients receiving trastuzumab with or without chemotherapy

Annals of Oncology

Volumn 12, Issue SUPPL. 1, 2001, Pages

  Gianni, L ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Adverse events; Cardiotoxicity; Herceptin ; Metastatic breast cancer; Safety; Trastuzumab

Indexed keywords

ANTHRACYCLINE; CIMETIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; EPIRUBICIN; MONOCLONAL ANTIBODY; PACLITAXEL; PARACETAMOL; PETHIDINE; TRASTUZUMAB;

ABDOMINAL PAIN; ARTICLE; ASTHENIA; CANCER THERAPY; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEVER; HEADACHE; HUMAN; IMMUNE SYSTEM; NAUSEA; PAIN; PATIENT CARE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SEPSIS; THORAX PAIN; VERTIGO; VOMITING;

EID: 0034872172     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/12.suppl_1.S63     Document Type: Article

References (23)

1. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
2. Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neu oncogene
3. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
4. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer, a paradigm for the development of macromolecular markers - A review
5. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer
6. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease
7. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
8. 3 cells
9. HER2 antibody for human cancer therapy
10. Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
11. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
12. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
13. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
14. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
15. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity
16. HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory chemotherapy treatment
17. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
18. Addition of Herceptin™ (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized, multinational, III trial
19. Doxorubicin-induced cardiomyopathy
20. A clinicopathologic analysis of Adriamycin cardiotoxicity
21. Risk factors for doxorubicin-induced congestive heart failure
22. Role of iron in anthracycline cardiotoxicity: New tunes for an old song?
23. Neuregulins promote survival and growth of cardiac myocytes